David W Reid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2163638/publications.pdf

Version: 2024-02-01

137 5,190 39 67
papers citations h-index g-index

137 137 137 6144
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Pathophysiological Response to SARS-CoV-2 Infection Detected by Infrared Spectroscopy Enables Rapid and Robust Saliva Screening for COVID-19. Biomedicines, 2022, 10, 351.	3.2	14
2	Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial. Journal of Cystic Fibrosis, 2021, 20, 316-323.	0.7	4
3	Outcomes of artery embolisation for cystic fibrosis patients with haemoptysis: a 20â€year experience at a major Australian tertiary centre. Internal Medicine Journal, 2021, 51, 1526-1529.	0.8	O
4	Increased susceptibility of cystic fibrosis airway epithelial cells to ferroptosis. Biological Research, 2021, 54, 38.	3.4	13
5	Investigating the Links between Lower Iron Status in Pregnancy and Respiratory Disease in Offspring Using Murine Models. Nutrients, 2021, 13, 4461.	4.1	2
6	Increased physical activity post-exacerbation is associated with decreased systemic inflammation in cystic fibrosis – An observational study. Physiotherapy Theory and Practice, 2020, 36, 1457-1465.	1.3	2
7	COVID-19 in a complex obstetric patient with cystic fibrosis. Infection, Disease and Health, 2020, 25, 239-241.	1.1	6
8	A Cohort Study of Sleep Quality in Adult Patients with Acute Pulmonary Exacerbations of Cystic Fibrosis. Internal Medicine Journal, 2020, , .	0.8	3
9	The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Frontiers in Immunology, 2020, 11, 303.	4.8	219
10	Centralised versus outreach models of cystic fibrosis care should be tailored to the needs of the individual patient. Internal Medicine Journal, 2020, 50, 232-235.	0.8	0
11	The Iron-chelator, N,N'-bis (2-hydroxybenzyl) Ethylenediamine-N,N'-diacetic acid is an Effective Colistin Adjunct against Clinical Strains of Biofilm-Dwelling Pseudomonas aeruginosa. Antibiotics, 2020, 9, 144.	3.7	14
12	Cancer-protective effects of inhaled corticosteroids in COPD are likely related to modification of epithelial activation. European Respiratory Journal, 2019, 54, 1901088.	6.7	1
13	Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. Gene, 2019, 683, 12-17.	2.2	6
14	Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta) Tj ETQq0 0 C 271-277.) rgBT /Ov 0.7	erlock 10 Tf ! 18
15	Genomic and phenotypic comparison of environmental and patient-derived isolates of Pseudomonas aeruginosa suggest that antimicrobial resistance is rare within the environment. Journal of Medical Microbiology, 2019, 68, 1591-1595.	1.8	16
16	Efficient zinc uptake is critical for the ability of Pseudomonas aeruginosa to express virulence traits and colonize the human lung. Journal of Trace Elements in Medicine and Biology, 2018, 48, 74-80.	3.0	30
17	Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
18	Anomalies in T Cell Function Are Associated With Individuals at Risk of Mycobacterium abscessus Complex Infection. Frontiers in Immunology, 2018, 9, 1319.	4.8	18

#	Article	IF	CITATIONS
19	Tropical Australia is a potential reservoir of non-tuberculous mycobacteria in cystic fibrosis. European Respiratory Journal, 2017, 49, 1700046.	6.7	11
20	A first step to STOP cystic fibrosis exacerbations. Journal of Cystic Fibrosis, 2017, 16, 529-531.	0.7	7
21	The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. Journal of Cystic Fibrosis, 2017, 16, 70-77.	0.7	34
22	Transforming growth factor (TGF) β ₁ and Smad signalling pathways: A likely key to <scp>EMT</scp> â€associated <scp>COPD</scp> pathogenesis. Respirology, 2017, 22, 133-140.	2.3	74
23	Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD. International Journal of COPD, 2016, Volume 11, 2359-2367.	2.3	36
24	<scp><i>P</i></scp> <i>seudomonas aeruginosa</i> antibiotic resistance in <scp>A</scp> ustralian cystic fibrosis centres. Respirology, 2016, 21, 329-337.	2.3	43
25	Acute exacerbation of COPD. Respirology, 2016, 21, 1152-1165.	2.3	213
26	Methicillin-resistant Staphylococcus aureus acquisition in healthcare workers with cystic fibrosis: a retrospective cross-sectional study. BMC Pulmonary Medicine, 2016, 16, 78.	2.0	8
27	Preliminary feasibility and modelling of a liquid matrix <i>Dictyostelium discoideum</i> virulence assay for <i>Pseudomonas aeruginosa</i> . British Journal of Biomedical Science, 2016, 73, 51-55.	1.3	6
28	Use of inhaled corticosteroids in COPD: improving efficacy. Expert Review of Respiratory Medicine, 2016, 10, 339-350.	2.5	7
29	An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis. BMC Pulmonary Medicine, 2015, 15, 116.	2.0	23
30	Prospective outcomes in patients with acute exacerbations of chronic obstructive pulmonary disease presenting to hospital: a generalisable clinical audit. Internal Medicine Journal, 2015, 45, 925-933.	0.8	14
31	Inhaled Antibiotics in Cystic Fibrosis (CF) and Non-CF Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 267-286.	2.1	30
32	The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis. Lancet Respiratory Medicine, the, 2015, 3, 640-650.	10.7	26
33	High Peripheral Blood Th17 Percent Associated with Poor Lung Function in Cystic Fibrosis. PLoS ONE, 2015, 10, e0120912.	2.5	30
34	Urease production as a marker of virulence in <i>Pseudomonas aeruginosa</i> Biomedical Science, 2014, 71, 175-176.	1.3	10
35	A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial–mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. International Journal of COPD, 2014, 9, 533.	2.3	70
36	Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease. International Journal of COPD, 2014, 9, 853.	2.3	35

#	Article	IF	Citations
37	Elevated metal concentrations in the CF airway correlate with cellular injury and disease severity. Journal of Cystic Fibrosis, 2014, 13, 289-295.	0.7	71
38	Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. European Respiratory Journal, 2014, 44, 922-930.	6.7	71
39	Reduced Mucosal Associated Invariant T-Cells Are Associated with Increased Disease Severity and Pseudomonas aeruginosa Infection in Cystic Fibrosis. PLoS ONE, 2014, 9, e109891.	2.5	58
40	Challenges of providing care to adults with cystic fibrosis., 2014,, 286-303.		1
41	<scp>ICU</scp> outcomes in cystic fibrosis following invasive ventilation. Respirology, 2013, 18, 585-586.	2.3	2
42	Accurate assessment of systemic iron status in cystic fibrosis will avoid the hazards of inappropriate iron supplementation. Journal of Cystic Fibrosis, 2013, 12, 303-304.	0.7	7
43	Pseudomonas aeruginosa Uses Multiple Pathways To Acquire Iron during Chronic Infection in Cystic Fibrosis Lungs. Infection and Immunity, 2013, 81, 2697-2704.	2.2	116
44	Developing an international <i>Pseudomonas aeruginosa</i> reference panel. MicrobiologyOpen, 2013, 2, 1010-1023.	3.0	94
45	Targeting iron uptake to control <i>Pseudomonas aeruginosa</i> infections in cystic fibrosis. European Respiratory Journal, 2013, 42, 1723-1736.	6.7	67
46	Sputum neutrophils in cystic fibrosis patients display a reduced respiratory burst. Journal of Cystic Fibrosis, 2013, 12, 352-362.	0.7	42
47	Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 688-699.	0.7	21
48	Shared <i>Pseudomonas aeruginosa</i> genotypes are common in Australian cystic fibrosis centres. European Respiratory Journal, 2013, 41, 1091-1100.	6.7	59
49	Pilot evaluation of web enabled symptom monitoring in cystic fibrosis. Informatics for Health and Social Care, 2013, 38, 354-365.	2.6	23
50	Ivacaftor in severe cystic fibrosis lung disease and a <scp>G</scp> 551 <scp>D</scp> mutation. Respirology Case Reports, 2013, 1, 52-54.	0.6	8
51	Changes in Airway Histone Deacetylase2 in Smokers and COPD with Inhaled Corticosteroids: A Randomized Controlled Trial. PLoS ONE, 2013, 8, e64833.	2.5	33
52	Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesis. European Respiratory Journal, 2012, 39, 1361-1367.	6.7	31
53	Cigarette smoke and platelet-activating factor receptor dependent adhesion of <i>Streptococcus pneumoniae </i> to lower airway cells. Thorax, 2012, 67, 908-913.	5.6	65
54	Reticular Basement Membrane Vessels Are Increased in COPD Bronchial Mucosa by Both Factor VIII and Collagen IV Immunostaining and Are Hyperpermeable. Journal of Allergy, 2012, 2012, 1-10.	0.7	10

#	Article	IF	Citations
55	S89â€Epithelial Mesenchymal Transition (EMT) in Chronic Obstructive Pulmonary Disease (COPD) Airways is Attenuated by Inhaled Corticosteroids (ICS): Abstract S89 Table 1. Thorax, 2012, 67, A43.1-A43.	5.6	O
56	Hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome in a 26-year-old woman with cystic fibrosis: a case report. Journal of Medical Case Reports, 2012, 6, 134.	0.8	0
57	Vessel-Associated Transforming Growth Factor-Beta1 (TGF- \hat{I}^21) Is Increased in the Bronchial Reticular Basement Membrane in COPD and Normal Smokers. PLoS ONE, 2012, 7, e39736.	2.5	42
58	Clinical trial of community nurse mentoring to improve self-management in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2012, 7, 407.	2.3	38
59	Molecular detection of <i>Haemophilus influenzae</i> in COPD sputum is superior to conventional culturing methods. British Journal of Biomedical Science, 2012, 69, 37-39.	1.3	3
60	Distinctive characteristics of bronchial reticular basement membrane and vessel remodelling in chronic obstructive pulmonary disease (COPD) and in asthma: they are not the same disease. Histopathology, 2012, 60, 964-970.	2.9	34
61	Changes in cystic fibrosis mortality in Australia, 1979–2005. Medical Journal of Australia, 2011, 195, 392-395.	1.7	39
62	Antimicrobial susceptibility testing of cystic fibrosis and non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa: a comparison of three methods. British Journal of Biomedical Science, 2011, 68, 1-4.	1.3	9
63	Decreased virulence of cystic fibrosis Pseudomonas aeruginosa in Dictyostelium discoideum. Microbiology and Immunology, 2011, 55, 224-230.	1.4	11
64	Superior vena cava obstruction due to total implantable venous access devices in cystic fibrosis: Case series and review. Respiratory Medicine CME, 2011, 4, 99-104.	0.1	1
65	Pseudomonas siderophores in the sputum of patients with cystic fibrosis. BioMetals, 2011, 24, 1059-1067.	4.1	87
66	Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respiratory Research, 2011, 12, 130.	3.6	109
67	Lung health care for Aboriginal and Torres Strait Islander Queenslanders: breathing easy is not so easy. Australian Health Review, 2011, 35, 512.	1.1	17
68	The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. American Journal of Clinical Nutrition, 2011, 93, 1006-1011.	4.7	265
69	Treatment of pulmonary exacerbations in cystic fibrosis. Therapy: Open Access in Clinical Medicine, 2011, 8, 623-643.	0.2	1
70	Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study. Respiratory Research, 2010, 11, 105.	3.6	65
71	Populationâ€based study of cystic fibrosis disease severity and haemochromatosis gene mutations. Respirology, 2010, 15, 141-149.	2.3	5
72	Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology, 2010, 15, 930-938.	2.3	147

#	Article	IF	CITATIONS
73	Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. International Journal of COPD, 2010, 5, 327.	2.3	18
74	Virulence gene distribution in clinical, nosocomial and environmental isolates of Pseudomonas aeruginosa. Journal of Medical Microbiology, 2010, 59, 881-890.	1.8	85
75	Biosignificance of bacterial cyanogenesis in the CF lung. Journal of Cystic Fibrosis, 2010, 9, 158-164.	0.7	33
76	Atypical presentation of acute pancreatitis in a man with pancreatic insufficiency and cystic fibrosis: a case report. Journal of Medical Case Reports, 2010, 4, 275.	0.8	3
77	Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions. Journal of Medical Microbiology, 2009, 58, 765-773.	1.8	94
78	Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2009, 47, 1503-1509.	3.9	52
79	Role of lung iron in determining the bacterial and host struggle in cystic fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L795-L802.	2.9	45
80	Iron chelation directed against biofilms as an adjunct to conventional antibiotics. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L857-L858.	2.9	13
81	Granulomatous angiitis leading to a pulmonary veno-occlusive disease-like picture. European Respiratory Journal, 2009, 33, 666-669.	6.7	9
82	Epidemiology of Pseudomonas aeruginosa in a tertiary referral teaching hospital. Journal of Hospital Infection, 2009, 73, 151-156.	2.9	18
83	Iron acquisition by Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. BioMetals, 2009, 22, 53-60.	4.1	67
84	Increased vascular permeability precedes cellular inflammation as asthma control deteriorates. Clinical and Experimental Allergy, 2009, 39, 1659-1667.	2.9	50
85	Chelated iron as an anti- <i>Pseudomonas aeruginosa</i> biofilm therapeutic strategy. Journal of Applied Microbiology, 2009, 106, 1058-1058.	3.1	9
86	Airway inflammation and antiâ€protease defences rapidly improve during treatment of an acute exacerbation of COPD. Respirology, 2009, 14, 495-503.	2.3	31
87	Sugar sweet and deadly?. Microbiology (United Kingdom), 2009, 155, 665-666.	1.8	2
88	Tolerance and rebound with zafirlukast in patients with persistent asthma. Journal of Negative Results in BioMedicine, 2008, 7, 3.	1.4	3
89	Bronchodilator reversibility, airway eosinophilia and antiâ€inflammatory effects of inhaled fluticasone in COPD are not related. Respirology, 2008, 13, 799-809.	2.3	30
90	Poor clinical outcomes associated with a multiâ€drug resistant clonal strain of <i>Pseudomonas aeruginosa</i> in the Tasmanian cystic fibrosis population. Respirology, 2008, 13, 886-892.	2.3	51

#	Article	IF	Citations
91	Angiogenesis: A potentially critical part of remodelling in chronic airway diseases?., 2008, 118, 128-137.		49
92	Management dilemma; a woman with cystic fibrosis and severe lung disease presenting with colonic carcinoma: a case report. Journal of Medical Case Reports, 2008, 2, 384.	0.8	2
93	Cystic fibrosis: ironing out the problem of infection?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L23-L24.	2.9	8
94	Bacterial cyanogenesis occurs in the cystic fibrosis lung. European Respiratory Journal, 2008, 32, 329-333.	6.7	44
95	Seasonal comparison of energy and nutrient intakes from food diaries completed for a longitudinal study. Proceedings of the Nutrition Society, 2008, 67, .	1.0	1
96	Vascular remodelling in asthma. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 39-43.	2.3	47
97	Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology (United Kingdom), 2007, 153, 3264-3274.	1.8	96
98	Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. Thorax, 2007, 62, 314-319.	5 . 6	69
99	Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. European Respiratory Journal, 2007, 30, 286-292.	6.7	109
100	Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling. European Respiratory Journal, 2007, 30, 574-588.	6.7	23
101	Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology, 2007, 12, 63-69.	2.3	60
102	Scuba diving, swimming and pulmonary oedema. Internal Medicine Journal, 2007, 37, 345-347.	0.8	7
103	Airway cell and cytokine changes in early asthma deterioration after inhaled corticosteroid reduction. Clinical and Experimental Allergy, 2007, 37, 1189-1198.	2.9	11
104	Airway distensibility in normal and asthmatic subjects and partitioning of the Fowler dead space. Applied Physiology, Nutrition and Metabolism, 2006, 31, 460-466.	1.9	1
105	Biofilm dispersal and exacerbations of cystic fibrosis lung disease. Pediatric Pulmonology, 2006, 41, 1254-1254.	2.0	1
106	Anaerobic culture conditions favor biofilm-like phenotypes inPseudomonas aeruginosaisolates from patients with cystic fibrosis. FEMS Immunology and Medical Microbiology, 2006, 48, 373-380.	2.7	30
107	Increased Vascular Endothelial Growth Factor and Receptors. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1201-1207.	5 . 6	128
108	Interâ€relationships between airway inflammation, reticular basement membrane thickening and bronchial hyperâ€reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis. Clinical and Experimental Allergy, 2005, 35, 1565-1571.	2.9	52

#	Article	IF	Citations
109	Exhaled NO in diffuse alveolar haemorrhage. Thorax, 2005, 60, 614-615.	5.6	6
110	Bronchial hyperresponsiveness and the bronchiolitis obliterans syndrome after lung transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 489-492.	0.6	15
111	Airway iron and iron-regulatory cytokines in cystic fibrosis. European Respiratory Journal, 2004, 24, 286-291.	6.7	78
112	Host response to transmissiblePseudomonas aeruginosa. European Respiratory Journal, 2004, 23, 493-494.	6.7	1
113	BAL eotaxin and IL-5 in asthma, and the effects of inhaled corticosteroid and beta2 agonist. Respirology, 2004, 9, 507-513.	2.3	17
114	Decreased lung capillary blood volume post-exercise is compensated by increased membrane diffusing capacity. European Journal of Applied Physiology, 2004, 93, 96-101.	2.5	14
115	Influence of High Altitude on Lung Development and Function. , 2004, , 267-275.		0
116	Microangiopathic haemolytic anaemia and thrombocytopenia following lung volume reduction surgery in a single lung transplant recipient on maintenance tacrolimus (FK506) therapy. Respirology, 2003, 8, 243-245.	2.3	2
117	Exhaled nitric oxide continues to reflect airway hyperresponsiveness and disease activity in inhaled corticosteroid-treated adult asthmatic patients. Respirology, 2003, 8, 479-486.	2.3	26
118	Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease. Internal Medicine Journal, 2003, 33, 572-577.	0.8	19
119	Revision of BTS guidelines for treatment of asthma. Thorax, 2003, 58, 280-280.	5.6	1
120	Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma <i>in vivo</i> . European Respiratory Journal, 2003, 21, 994-999.	6.7	74
121	Iron Deficiency in Cystic Fibrosis. Chest, 2002, 121, 48-54.	0.8	106
122	Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax, 2002, 57, 309-316.	5.6	355
123	GM-CSF therapy in pulmonary alveolar proteinosis. Thorax, 2002, 57, 837-837.	5.6	17
124	Management of chronic obstructive pulmonary disease in the twenty-first century. Internal Medicine Journal, 2002, 32, 361-361.	0.8	0
125	Normally suppressing CD40 coregulatory signals delivered by airway macrophages to TH2 lymphocytes are defective in patients with atopic asthma. Journal of Allergy and Clinical Immunology, 2001, 107, 863-870.	2.9	21
126	Iron overload and nitric oxide-derived oxidative stress following lung transplantation. Journal of Heart and Lung Transplantation, 2001, 20, 840-849.	0.6	24

#	Article	IF	CITATIONS
127	Bronchoalveolar lavage macrophage and lymphocyte phenotypes in lung transplant recipients. Journal of Heart and Lung Transplantation, 2001, 20, 1064-1074.	0.6	38
128	Corticosteroids for acute severe asthma in hospitalised patients. The Cochrane Library, 2001, , .	2.8	82
129	Reduced Airway Distensibility, Fixed Airflow Limitation, and Airway Wall Remodeling in Asthma. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1718-1721.	5.6	139
130	Inhaled Triamcinolone and Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2001, 344, 1553-1556.	27.0	0
131	Management and treatment perceptions among young adults with asthma in Melbourne: The Australian experience from the European Community Respiratory Health Survey. Respirology, 2000, 5, 281-287.	2.3	28
132	A critical evaluation of the MefarTM dosimeter. European Respiratory Journal, 1999, 14, 430-434.	6.7	6
133	A double-blind placebo-controlled study of the effect of influenza vaccination on airway responsiveness in asthma. Respiratory Medicine, 1998, 92, 1010-1011.	2.9	15
134	Nebulizer calibration using lithium chloride: an accurate, reproducible and user-friendly method. European Respiratory Journal, 1998, 11, 937-941.	6.7	5
135	Age-dependent inaccuracy of asthma death certification in Northern England, 1991–1992. European Respiratory Journal, 1998, 12, 1079-1083.	6.7	28
136	Lower Lobe Consolidation and Pyopneumothorax. Chest, 1997, 112, 1117-1119.	0.8	1
137	Variation in nebulizer output and weight output from Mefar dosimeter: implications for multicentre studies. European Respiratory Journal, 1997, 10, 2436-2437.	6.7	5